Optimum chemotherapy for the management of advanced biliary tract cancer

被引：9
作者：
Ghosn, Marwan [1 ]
Kourie, Hampig Raphael [1 ]
El Rassy, Elie [1 ]
Chebib, Ralph [1 ]
El Karak, Fadi [1 ]
Hanna, Colette [1 ]
Nasr, Dolly [1 ]
机构：
[1] St Joseph Univ, Dept Oncol, Fac Med, Beirut 20383054, Lebanon
来源：
WORLD JOURNAL OF GASTROENTEROLOGY | 2015年 / 21卷 / 14期
关键词：
Biliary tract cancer; Chemotherapy; Updates; Treatment modalities; Novel therapies; PHASE-II TRIAL; GALLBLADDER CARCINOMA; CHOLANGIOCARCINOMA; GEMCITABINE; CISPLATIN; COMBINATION; MULTICENTER; ERLOTINIB; EXPRESSION; SORAFENIB;
D O I：
10.3748/wjg.v21.i14.4121
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Biliary tract cancers (BTCs) are highly fatal malignancies, which are often diagnosed at an advanced stage and have relatively poor prognosis. The treatment of patients with advanced BTC is systemic, based on chemotherapy or best supportive care, depending on their performance status. Despite clinical trials studying many chemotherapeutic regimens and targeted therapies for the treatment of BTC, the standard of care for advanced BTC remains the combination of gemcitabine with cisplatin. Many new molecules targeting proliferation and survival pathways, the immune response and angiogenesis are currently undergoing phase. and. trials for the treatment of advanced BTC with promising results.
引用
收藏
页码：4121 / 4125
页数：5
相关论文
共 36 条
[1]   Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers [J].
Bekaii-Saab, Tanios ;
Phelps, Mitch A. ;
Li, Xiaobai ;
Saji, Motoyasu ;
Goff, Laura ;
Kauh, John Sae Wook ;
O'Neil, Bert H. ;
Balsom, Stephanie ;
Balint, Catherine ;
Liersemann, Ryan ;
Vasko, Vasily V. ;
Bloomston, Mark ;
Marsh, William ;
Doyle, L. Austin ;
Ellison, Gilian ;
Grever, Michael ;
Ringel, Matthew D. ;
Villalona-Calero, Miguel A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) :2357-2363
[2]   Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial [J].
Bengala, C. ;
Bertolini, F. ;
Malavasi, N. ;
Boni, C. ;
Aitini, E. ;
Dealis, C. ;
Zironi, S. ;
Depenni, R. ;
Fontana, A. ;
Del Giovane, C. ;
Luppi, G. ;
Conte, P. .
BRITISH JOURNAL OF CANCER, 2010, 102 (01) :68-72
[3]  
Buzzoni R, 2010, ASCO M S, V28
[4]  
Costello MR, 2009, J CLIN ONCOL, V27
[5]   Medical progress - Biliary tract cancers [J].
de Groen, PC ;
Gores, GJ ;
LaRusso, NF ;
Gunderson, LL ;
Nagorney, DM .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (18) :1368-1378
[6]   A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial [J].
Ducreux, M ;
van Cutsem, E ;
van Laethern, JL ;
Gress, TM ;
Jeziorski, K ;
Rougier, P ;
Wagener, T ;
Anak, O ;
Baron, B ;
Nordlinger, B .
EUROPEAN JOURNAL OF CANCER, 2005, 41 (03) :398-403
[7]   Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials [J].
Eckel, F. ;
Schmid, R. M. .
BRITISH JOURNAL OF CANCER, 2007, 96 (06) :896-902
[8]   S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma [J].
El-Khoueiry, A. B. ;
Rankin, C. ;
Siegel, A. B. ;
Iqbal, S. ;
Gong, I-Y ;
Micetich, K. C. ;
Kayaleh, O. R. ;
Lenz, H-J ;
Blanke, C. D. .
BRITISH JOURNAL OF CANCER, 2014, 110 (04) :882-887
[9]   SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma [J].
El-Khoueiry, Anthony B. ;
Rankin, Cathryn J. ;
Ben-Josef, Edgar ;
Lenz, Heinz-Josef ;
Gold, Philip J. ;
Hamilton, R. Darryl ;
Govindarajan, Rangaswamy ;
Eng, Cathy ;
Blanke, Charles D. .
INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) :1646-1651
[10]  
Finn RS, 2012, J CLIN ONCOL S4, V30
1234